[In vitro antifungal activity of ravuconazole against isolates of dermatophytes and Candida species from patients with dermatomycoses].

The in vitro activity of ravuconazole (RVCZ) was compared with those of itraconazole (ITCZ) and terbinafine (TBF) against 73 dermatophyte isolates and 18 Candida spp. isolates recovered from patients with dermatomycosis at 4 dermatological clinics in Japan in 2011. The dermatophyte isolates consisted of Trichophyton rubrum (n=51), Trichophyton mentagrophytes (n=20 : these strains were not identified by molecular phylogenetic analysis.), Trichophyton tonsurans (n=1), and Microsporum canis (n=1). The Candida spp. isolates comprised C. albicans (n=11), C. parapsilosis (n=5), C. guilliermondii (n=1), and C. pseudohaemulonii (n=1). RVCZ was highly active against all dermatophytes and all Candida spp. : the geometric mean (GM) MICs for T. rubrum and T. mentagrophytes were 0.035 μg/mL and MICs for T. tonsurans and M. canis were ≤ 0.03 μg/mL, and GM MICs for C. albicans and C. parapsilosis were ≤ 0.03 μg/mL and MICs for C. guilliermondii and C. pseudohaemulonii were 0.25 and ≤ 0.03 μg/mL, respectively. Compared to RVCZ, ITCZ showed similar anti-dermatophytic and anti-Candida activities, while TBF had a slightly higher anti-dermatophytic but a markedly lower anti-Candida activity. These results suggest that RVCZ is a potential candidate systemic antifungal therapy against onychomycosis and other dermatomycoses that are refractory to topical antifungal therapy.

[1]  C. Grover,et al.  An update on treatment of onychomycosis , 2012, Mycoses.

[2]  E. Chryssanthou,et al.  Epidemiology of dermatophyte infections in Stockholm, Sweden: a retrospective study from 2005-2009. , 2010, Medical mycology.

[3]  Aditya K. Gupta,et al.  Onychomycosis therapy: past, present, future. , 2010, Journal of drugs in dermatology : JDD.

[4]  S. Suh,et al.  Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  M. Takashima,et al.  Candida pseudohaemulonii Sp. Nov., an Amphotericin B‐ and Azole‐Resistant Yeast Species, Isolated from the Blood of a Patient from Thailand , 2006, Microbiology and immunology.

[6]  C. Leonardi,et al.  A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  A. Gupta,et al.  In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. , 2005, Medical mycology.

[8]  C. Romano,et al.  Retrospective study of onychomycosis in Italy: 1985–2000 , 2005, Mycoses.

[9]  B. Elewski,et al.  Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. , 2004, Journal of the American Academy of Dermatology.

[10]  E. Svejgaard,et al.  Onychomycosis in Denmark: prevalence of fungal nail infection in general practice , 2004, Mycoses.

[11]  Andrew M. Johnson,et al.  Cumulative meta‐analysis of systemic antifungal agents for the treatment of onychomycosis , 2004, The British journal of dermatology.

[12]  M. Pfaller,et al.  In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp , 2002, Antimicrobial Agents and Chemotherapy.

[13]  M. Pfaller,et al.  International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program , 2001, Journal of Clinical Microbiology.

[14]  D. Denning,et al.  In Vitro Activity of the New Triazole BMS-207147 againstAspergillus Species in Comparison with Itraconazole and Amphotericin B , 2000, Antimicrobial Agents and Chemotherapy.

[15]  B. Elewski.  Onychomycosis. Treatment, quality of life, and economic issues. , 2000, American journal of clinical dermatology.

[16]  T. C. White,et al.  In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole. , 1999, Diagnostic microbiology and infectious disease.

[17]  M. Pfaller,et al.  In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America , 1999, Antimicrobial Agents and Chemotherapy.

[18]  B S Schlefman,et al.  Onychomycosis: a compendium of facts and a clinical experience. , 1999, The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons.

[19]  A. del Palacio,et al.  [Dermatophytes isolated in Hospital Universitario 12 de Octubre (Madrid, Spain).]. , 1999, Revista iberoamericana de micologia.

[20]  M. Brandt,et al.  In Vitro Susceptibilities of CandidaBloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole , 1998, Antimicrobial Agents and Chemotherapy.

[21]  K. Katsu,et al.  Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis , 1996, Antimicrobial agents and chemotherapy.

[22]  T. White.  Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics , 1990 .